Therapy Detail

Therapy Name Ixazomib
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ixazomib Ninlaro MLN9708 Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lymphoma not applicable Ixazomib Preclinical Actionable In a preclinical study, Ixazomib (MLN9708) inhibited survival and induced apoptosis in T-cell lymphoma cell lines in culture, and reduced tumor volume in xenograft models (PMID: 26988986). 26988986
Unknown unknown Hodgkin's lymphoma not applicable Ixazomib Preclinical Actionable In a preclinical study, Ixazomib (MLN9708) inhibited survival and induced apoptosis in Hodgkin's lymphoma cell lines in culture, and reduced tumor volume in xenograft models (PMID: 26988986). 26988986
NPM1 exon12 acute myeloid leukemia predicted - sensitive Ixazomib Clinical Study Actionable In a clinical study, Ixazomib (MLN9708) treatment resulted in significantly reduced peripheral blast cells in a NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia (AML) patient, and demonstrated selective toxicity towards NPMc+ AML cell lines in culture (PMID: 26634271). 26634271
Clinical Trial Phase Therapies Title Recruitment Status
NCT02504359 Phase I Ixazomib Carmustine + Cytarabine + Etoposide + Melphalan Tacrolimus + Methotrexate Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Recruiting
NCT02440464 Phase II Tacrolimus + Methotrexate Ixazomib Fludarabine + Melphalan Bortezomib Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Active, not recruiting